MLTX LAWSUIT: MoonLake Immunotherapeutics Investors are Notified to Contact BFA Law about the Filed Securities Fraud Class Action and Important December 15 Deadline

Core Viewpoint - A lawsuit has been filed against MoonLake Immunotherapeutics for potential violations of federal securities laws, with a significant deadline for investors to act by December 15, 2025 [1][3]. Group 1: Lawsuit Details - The lawsuit is pending in the U.S. District Court for the Southern District of New York, captioned Peters v. MoonLake Immunotherapeutics, et al., No. 1:25-cv-08612 [3]. - Investors are encouraged to contact BFA Law for more information and to potentially lead the case [2][8]. Group 2: Company Background - MoonLake Immunotherapeutics is a clinical-stage biotechnology company focused on developing therapies for inflammatory diseases [4]. - The company conducted Phase 3 VELA trials for sonelokimab (SLK), aimed at treating moderate to severe hidradenitis suppurativa [4]. Group 3: Allegations and Impact - The complaint alleges that MoonLake misrepresented its clinical data and the benefits of SLK's Nanobody structure compared to traditional monoclonal antibody treatments [5][6]. - Following the announcement of disappointing results from the VELA trials on September 28, 2025, MoonLake's stock price plummeted nearly 90%, from $61.99 to $6.24 per share [7].